Data Sheet (Cat.No.T14524)

TargetMol
A DRUG SCREENING EXPERT

Befetupitant

Chemical Properties



CAS No.:	290296-68-3
Formula:	C29H29F6N3O2
Molecular Weight:	565.55
Appearance:	N/A
Storage:	0-4℃ for short term (days to weeks), or -20℃ for long term (months).

Biological Description

Description	Befetupitant is a competitive tachykinin 1 receptor (NK1R) antagonist.
Targets(IC_{50})	NK1R: None
In vivo	Befetupitant is a different, highly selective NK1R antagonist. Which is tested in the alkali burn model. Topical application of Befetupitant for 4 days is effective (P<0.05) in reducing hemangiogenesis and lymphangiogenesis at both concentrations (0.4 and 1.6 mg/mL). Befetupitant and its vehicle DMSO, however, induced corneal opacity even in healthy controls, as observed at slit-lamp examination. Fluorescein and hematoxylin-eosin staining showed epithelial damage and inflammatory cellular infiltration in the stroma, respectively, confirming DMSO toxicity. Topical application of Befetupitant reduces corneal neovascularization (CNV) in the alkali burn model but is toxic owing to the vehicle (DMSO). Befetupitant is not tested in the suture model[1].

Solubility Information

Solubility	< 1 mg/ml refers to the product slightly soluble or insoluble

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.768 mL	8.841 mL	17.682 mL
5 mM	0.354 mL	1.768 mL	3.536 mL
10 mM	0.177 mL	0.884 mL	1.768 mL
50 mM	0.035 mL	0.177 mL	0.354 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 ℃ for 6 months; - 20 ℃ for 1 month. Please use it as soon as possible.

Reference

1. Bignami F, et al. NK1 receptor antagonists as a new treatment for corneal neovascularization. Invest Ophthalmol Vis Sci. 2014 Sep 16;55(10):6783-94.

Inhibitors · Natural Compounds · Compound Libraries

Tel:781-999-4286 E-mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481